Subclinical hypothyroidism (SCH) should be considered in two categories according to the elevation in serum thyroid-stimulating hormone (TSH) level: mildly increased TSH levels (4.0-10.0 mU/l) and more severely increased TSH value (>10 mU/l). An initially raised serum TSH, with FT4 within reference range, should be investigated with a repeat measurement of both serum TSH and FT4, along with thyroid peroxidase antibodies, preferably after a 2- to 3-month interval. Even in the absence of symptoms, replacement therapy with L-thyroxine is recommended for younger patients (<65-70 years) with serum TSH >10 mU/l. In younger SCH patients (serum TSH <10 mU/l) with symptoms suggestive of hypothyroidism, a trial of L-thyroxine replacement therapy should be considered. For such patients who have been started on L-thyroxine for symptoms attributed to SCH, response to treatment should be reviewed 3 or 4 months after a serum TSH within reference range is reached. If there is no improvement in symptoms, L-thyroxine therapy should generally be stopped. Age-specific local reference ranges for serum TSH should be considered in order to establish a diagnosis of SCH in older people. The oldest old subjects (>80-85 years) with elevated serum TSH ≤10 mU/l should be carefully followed with a wait-and-see strategy, generally avoiding hormonal treatment. If the decision is to treat SCH, then oral L-thyroxine, administered daily, is the treatment of choice. The serum TSH should be re-checked 2 months after starting L-thyroxine therapy, and dosage adjustments made accordingly. The aim for most adults should be to reach a stable serum TSH in the lower half of the reference range (0.4-2.5 mU/l). Once patients with SCH are commenced on L-thyroxine treatment, then serum TSH should be monitored at least annually thereafter.

Keywords:
Subclinical hypothyroidism, Thyrotropin, L-Thyroxine, Vascular risk, Cognition, Management
1.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC: The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534.
2.
Vanderpump MP, Tunbridge WM, French JM, et al: The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995;43:55-68.
3.
Surks MI, Ortiz E, Daniels GH, et al: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;29:228-238.
4.
Guyatt GH, Oxman AD, Vist GE, et al, GRADE Working Group: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.
5.
Kunz R, Vigersky RA, Guyatt GH, Montori VM: A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 2008;93:666-673.
6.
Hollowell JG, Staehling NW, Flanders WD, et al: Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-499.
7.
Vanderpump MP, Tunbridge WM: Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid 2002;12:839-847.
8.
Somwaru LL, Rariy CM, Arnold AM, Cappola AR: The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. J Clin Endocrinol Metab 2012;97:1962-1969.
9.
Evered DC, Ormston BJ, Smith PA, et al: Grades of hypothyroidism. Br Med J 1973;5854:657-662.
10.
Duntas LH: Subclinical hypothyroidism: a misnomer in search of a new name. Thyroid 2001;11:361-362.
11.
Roelfsema F, Pereira AM, Veldhuis JD, et al: Thyrotropin secretion profiles are not different in men and women. J Clin Endocrinol Metab 2009;94:3964-3967.
12.
Roelfsema F, Pereira AM, Adriaanse R, et al: Thyrotropin secretion in mild and severe primary hypothyroidism is distinguished by amplified burst mass and basal secretion with increased spikiness and approximate entropy. J Clin Endocrinol Metab 2010;95:928-934.
13.
Karmisholt J, Andersen S, Laurberg P: Variation in thyroid function tests in patients with stable untreated subclinical hypothyroidism. Thyroid 2008;18:303-308.
14.
Andersen S, Pedersen KM, Bruun NH, Laurberg P: Narrow individual variations in serum T4 and T3 in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002;87:1068-1072.
15.
Bremner AP, Feddema P, Leedman PJ, et al: Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab 2012;97:1554-1562.
16.
Alberti L, Proverbio MC, Costagliola S, et al: Germline mutations of TSH receptor gene as cause of nonautoimmune subclinical hypothyroidism. J Clin Endocrinol Metab 2002;87:2549-2555.
17.
Biondi B, Cooper DS: The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008;29:76-131.
18.
Surks MI, Hollowell JG: Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007;92:4575-4582.
19.
Atzmon G, Barzilai N, Hollowell JG, et al: Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab 2009;94:1251-1254.
20.
Persani L, Borgato S, Romoli R, et al: Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states. J Clin Endocrinol Metab 1998;83:2486-2492.
21.
Åsvold BO, Bjøto T, Vatten LJ: Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab 2009;94:5023-5027.
22.
Beever K, Bradbury J, Phillips D, et al: Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. Clin Chem 1989;35:1949-1954.
23.
Huber G, Staub JJ, Meier C, et al: Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002;87:3221-3226.
24.
Karmisholt J, Andersen S, Laurberg P: Variation in thyroid function in subclinical hypothyroidism: importance of clinical follow-up and therapy. Eur J Endocrinol 2011;164:317-323.
25.
Garber JR, Cobin RH, Gharib H, et al: Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012;22:1200-1235.
26.
Pedersen OM, Aardal NP, Larssen TB, et al: The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid 2000;10:251-259.
27.
Jorde R, Waterloo K, Storhaug H, et al: Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. J Clin Endocrinol Metab 2006;91:145-153.
28.
Villar HC, Saconato H, Valente O, Atallah AN: Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev 2007;3:CD003419.
29.
Razvi S, Ingoe L, Keeka G, et al: The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007;92:1715-1723.
30.
Joffe RT, Pearce EN, Hennessey JV, et al: Subclinical hypothyroidism, mood, and cognition in older adults: a review. Int J Geriatr Psychiatry 2013;28:111-118.
31.
Samuels MH, Schuff KG, Carlson NE, et al: Health status, mood, and cognition in experimentally induced subclinical hypothyroidism. J Clin Endocrinol Metab 2007;25:2545-2551.
32.
Baldini IM, Vita A, Mauri MC, et al: Psychopathological and cognitive features in subclinical hypothyroidism. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:925-935.
33.
Del Ser Quijano T, Delgado C, Martinez Espinosa S, Vazquez C: Cognitive deficiency in mild hypothyroidism. Neurologia 2000;15:193-198.
34.
Correia N, Mullally S, Cooke G, et al: Evidence for a specific defect in hippocampal memory in overt and subclinical hypothyroidism. J Clin Endocrinol Metab 2009;94:3789-3797.
35.
Aghili R, Khamseh ME, Malek M, et al: Changes of subtests of Wechsler Memory Scale and cognitive function in subjects with subclinical hypothyroidism following treatment with levothyroxine. Arch Med Sci 2012;8:1096-1101.
36.
Park YJ, Lee EJ, Lee YJ: Subclinical hypothyroidism (SCH) is not associated with metabolic derangement, cognitive impairment, depression or poor quality of life in elderly subjects. Arch Gerontol Geriatr 2010;50:e68-e73.
37.
Parle J, Roberts L, Wilson S, et al: A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid Study. J Clin Endocrinol Metab 2010;95:3623-3632.
38.
Monzani A, Prodam F, Rapa A, et al: Endocrine disorders in childhood and adolescence. Natural history of subclinical hypothyroidism in children and adolescents and potential effects of replacement therapy: a review. Eur J Endocrinol 2012;168:R1-R11.
39.
Verloop H, Louwerens M, Schoones JW, et al: Risk of hypothyroidism following hemithyroidectomy: systematic review and meta-analysis of prognostic studies. J Clin Endocrinol Metab 2012;97:2243-2255.
40.
Boelaert K: The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer 2009;16:1065-1072.
41.
Fiore E, Vitti P: Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012;97:1134-1145.
42.
Boelaert K, Horacek J, Holder RL, et al: Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006;91:4295-4301.
43.
Fiore E, Rago T, Provenzale MA, et al: L-Thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27,914 patients. Endocr Relat Cancer 2010;17:231-239.
44.
Haymart MR, Glinberg SL, Liu J, et al: Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) 2009;71:434-439.
45.
Kim SS, Lee BJ, Lee JC, et al: Preoperative serum thyroid-stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: a single-center experience. Endocrine 2011;39:259-265.
46.
Danforth E Jr, Horton ES, O'Connell M, et al: Dietary-induced alterations in thyroid hormone metabolism during overnutrition. J Clin Invest 1979;64:1336-1347.
47.
De Moura Souza A, Sichieri R: Association between serum TSH concentration within the normal range and adiposity. Eur J Endocrinol 2011;165:11-15.
48.
Kitahara CM, Platz EA, Ladenson PW, et al: Body fatness and markers of thyroid function among US men and women. PLoS One 2012;7:e34979.
49.
Nyrnes A, Jorde R, Sundsfjord J: Serum TSH is positively associated with BMI. Int J Obes (Lond) 2006;30:100-105.
50.
Fox CS, Pencina MJ, D'Agostino RB, et al: Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med 2008;168:587-592.
51.
Wolters B, Lass N, Reinehr T: TSH and free triiodothyronine concentrations are associated with weight loss in a lifestyle intervention and weight regain afterwards in obese children. Eur J Endocrinol 2013;168:323-329.
52.
Reinehr T, de Sousa G, Andler W: Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. J Clin Endocrinol Metab 2006;91:3088-3091.
53.
Dall'Asta C, Paganelli M, Morabito A, et al: Weight loss through gastric banding: effects on TSH and thyroid hormones in obese subjects with normal thyroid function. Obesity (Silver Spring) 2010;18:854-857.
54.
Chikunguwo S, Brethauer S, Nirujogi V, et al: Influence of obesity and surgical weight loss on thyroid hormone levels. Surg Obes Relat Dis 2007;3:631-635.
55.
Kadiyala R, Peter R, Okosieme OE: Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. Int J Clin Pract 2010;64:1130-1139.
56.
Triolo TM, Armstrong TK, McFann K, et al: Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 2011;34:1211-1213.
57.
Boelaert K, Newby PR, Simmonds MJ, et al: Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010;123:183.e1-e9.
58.
Perros P, McCrimmon RJ, Shaw G, Frier BM: Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med 1995;12:622-627.
59.
Kahaly GJ: Polyglandular autoimmune syndrome type 2. Presse Med 2012;41:e663-e670.
60.
Napier C, Pearce SH: Autoimmune Addison's disease. Presse Med 2012;41:e626-e635.
61.
Stryker TD, Molitch ME: Reversible hyperthyrotropinemia, hyperthyroxinemia, and hyperprolactinemia due to adrenal insufficiency. Am J Med 1985;79:271-276.
62.
Dimitriadis G, Mitrou P, Lambadiari V, et al: Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab 2006;91:4930-4937.
63.
Roos A, Bakker SJ, Links TP, et al: Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007;92:491-496.
64.
Maratou E, Hadjidakis DJ, Kollias A, et al: Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009;160:785-790.
65.
Visser WE, Heemstra KA, Swagemakers SM, et al: Physiological thyroid hormone levels regulate numerous skeletal muscle transcripts. J Clin Endocrinol Metab 2009;94:3487-3496.
66.
Stanická S, Vondra K, Pelikánová T, et al: Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clin Chem Lab Med 2005;43:715-720.
67.
Iwen A, Schroeder E, Brabant G: Thyroid hormones and the metabolic syndrome Eur J Thyroid, in press.
68.
Skarulis MC, Celi FS, Mueller E, et al: Thyroid hormone induced brown adipose tissue and amelioration of diabetes in a patient with extreme insulin resistance. J Clin Endocrinol Metab 2010;95:256-262.
69.
Tognini S, Polini A, Pasqualetti G, et al: Age and gender substantially influence the relationship between thyroid status and the lipoprotein profile: results from a large cross-sectional study. Thyroid 2012;22:1096-1103.
70.
Hak AE, Pols HA, Visser TJ, et al: Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000;132:270-278.
71.
Walsh JP, Bremner AP, Bulsara MK, et al: Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005;165:2467-2472.
72.
Boekholdt SM, Titan SM, Wiersinga WM, et al: Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. Clin Endocrinol (Oxf) 2010;72:404-410.
73.
Cooper DS: Clinical practice. Subclinical hypothyroidism. N Engl J Med 2001;345:260-265.
74.
Klein I: Subclinical hypothyroidism - just a high serum thyrotropin concentration or something else? J Clin Endocrinol Metab. 2013;98:508-510.
75.
Duntas LH, Brenta G: The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012;96:269-281.
76.
Pearce EN: Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012;97:326-333.
77.
Bindels AJ, Westendorp RG, Frölich M, et al: The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle-aged men and women: a need for case-finding? Clin Endocrinol 1999;50:217-220.
78.
Danese MD, Ladenson PW, Meinert CL, Powe NR: Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000;85:2993-3001.
79.
Tanis BC, Westendorp GJ, Smelt HM: Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a re-analysis of intervention studies. Clin Endocrinol 1996;44:643-649.
80.
Teixeira PF, Reuters VS, Ferreira MM, et al: Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial. Horm Metab Res 2008;40:50-55.
81.
Meier C, Staub JJ, Roth CB, et al: TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001;86:4860-4866.
82.
Caraccio N, Ferrannini E, Monzani F: Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002;87:1533-1538.
83.
Monzani F, Caraccio N, Kozàkowà M, et al: Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab 2004;89:2099-2106.
84.
Manninen V, Elo MO, Frick MH, et al: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651.
85.
Biondi B, Fazio S, Palmieri EA, et al: Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1999;84:2064-2067.
86.
Monzani F, Di Bello V, Caraccio N, et al: Effect of L-thyroxine on cardiac function and structure in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2001;86:1110-1115.
87.
Yazici M, Gorgulu S, Sertbas Y, et al: Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function. Int J Cardiol 2004;95:135-143.
88.
Biondi B: Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur J Endocrinol 2012;167:609-618.
89.
Taddei S, Caraccio N, Virdis A, et al: Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of L-thyroxine therapy. J Clin Endocrinol Metab 2003;88:3731-3737.
90.
Shakoor SK, Aldibbiat A, Ingoe LE, et al: Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapy. J Clin Endocrinol Metab 2010;95:319-322.
91.
Cabral MD, Teixeira PF, Silva NA, et al: Normal flow-mediated vasodilatation of the brachial artery and carotid artery intima-media thickness in subclinical hypothyroidism. Braz J Med Biol Res 2009;42:426-432.
92.
Gencer B, Collet TH, Virgini V, et al: Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from six prospective cohorts. Circulation 2012;126:1040-1049.
93.
Pasqualetti G, Tognini S, Polini A, et al: Is subclinical hypothyroidism a cardiovascular risk factor in the elderly? J Clin Endocrinol Metab 2013;98:2256-2266.
94.
Hyland KA, Arnold AM, Lee JS, Cappola AR: Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Clin Endocrinol Metab 2013;98:533-540.
95.
Nanchen D, Gussekloo J, Westendorp RG, et al, PROSPER Group: Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012;97:852-861.
96.
Iervasi G, Molinaro S, Landi P, et al: Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007;167:1526-1532.
97.
Rodondi N, Bauer DC, Cappola AR, et al: Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health Study. J Am Coll Cardiol 2008;52:1152-1159.
98.
Imaizumi M, Akahoshi M, Ichimaru S, et al: Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004;89:3365-3370.
99.
Cappola AR, Fried LP, Arnold AM, et al: Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006;295:1033-1041.
100.
Lindeman RD, Romero LJ, Schade DS, et al: Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. Thyroid 2003;13:595-600.
101.
Vanderpump MP, Tunbridge WM, French JM, et al: The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996;6:155-160.
102.
Parle JV, Maisonneuve P, Sheppard MC, et al: Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001;358:861-865.
103.
Tseng FY, Lin WY, Lin CC, et al: Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol 2012;60:730-737.
104.
Razvi S, Weaver JU, Vanderpump MP, Pearce SHS: The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: re-analysis of the Whickham Survey cohort. J Clin Endocrinol Metab 2010;95:1734-1740.
105.
Ochs N, Auer R, Bauer DC, et al: Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008;148:832-845.
106.
Rodondi N, den Elzen WP, Bauer DC, et al, Thyroid Studies Collaboration: Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010;304:1365-1374.
107.
Razvi S, Shakoor A, Weaver JU, et al: The influence of age on ischemic heart disease and mortality in subclinical hypothyroidism - a meta-analysis. J Clin Endocrinol Metab 2008;93:2998-3007.
108.
Razvi S, Weaver JU, Butler TJ, Pearce SHS: Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events and mortality. Arch Intern Med 2012;172:811-818.
109.
Gharib H, Tuttle RM, Baskin HJ, et al: Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005;90:581-585.
110.
Singh S, Duggal J, Molnar J, et al: Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2008;125:41-48.
111.
Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B: Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008;159:329-341.
112.
Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J: Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol 2004;61:232-238.
113.
Bremner AP, Feddema P, Leedman PJ, et al: Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab 2012;97:1554-1562.
114.
Strait JB, Lakatta EG: Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin 2012;8:143-164.
115.
Tetè S, Tripodi D, Rosati M, et al: Endothelial cells, cholesterol, cytokines, and aging. Int J Immunopathol Pharmacol 2012;25:355-363.
116.
Gussekloo J, van Exel E, Craen AJM, et al: Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004;292:2591-2599.
117.
Rozing MP, Houwing-Duistermaat JJ, Slagboom PE, et al: Familial longevity is associated with decreased thyroid function. J Clin Endocrinol Metab 2010;95:4979-4984.
118.
TRUST study website: www.trustthyroidtrial.com.
119.
Mooijaart SP, IEMO 80-plus Thyroid Trial Collaboration: Subclinical thyroid disorders. Lancet 2012;380:335.
120.
Meier C, Staub JJ, Roth CB, et al: TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001;86:4860-4866.
121.
Cooper DS, Halpern R, Wood LC, et al: L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med 1984;101:18-24.
122.
Nyström E, Caidahl K, Fager G, et al: A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical' hypothyroidism. Clin Endocrinol (Oxf) 1988;29:63-75.
123.
Jaeschke R, Guyatt G, Gerstein H, et al: Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 1996;11:744-749.
124.
Roos A, Linn-Rasker SP, van Domburg RT, et al: The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. Arch Intern Med 2005;165:1714-1720.
125.
Bach-Huynh TG, Nayak B, Loh J, et al: Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab 2009;94:3905-3912.
126.
Bolk N, Visser TJ, Nijman J, et al: Effects of evening vs. morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med 2010;170:1996-2003.
127.
Benvenga S, Bartolone L, Pappalardo MA, et al: Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 2008;18:293-301.
128.
Bell DS, Ovalle F: Use of soy protein supplement and resultant need for increased dose of levothyroxine. Endocr Pract 2001;7:193-194.
129.
Liwanpo L, Hershman JM: Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab 2009;23:781-792.
130.
Bevan JS, Munro JF: Thyroxine malabsorption following intestinal bypa ss surgery. Int J Obes 1986;10:245-246.
131.
Gkotsina M, Michalaki M, Mamali I, et al: Improved levothyroxine pharmacokinetics after bariatric surgery. Thyroid 2013;23:414-419.
132.
Grozinsky-Glasberg S, Fraser A, Nahshoni E,, et al: Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006;91:2592-2599.
133.
Wiersinga WM, Duntas L, Fadeyev V, et al: 2012 ETA Guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012;1:55-71.
134.
Parle JV, Franklyn JA, Cross KW, et al: Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991;34:77-83.
135.
Kabadi UM: ‘Subclinical hypothyroidism'. Natural course of the syndrome during a prolonged follow-up study. Arch Intern Med 1993;153:957-961.
136.
Huber G, Staub JJ, Meier C, et al: Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002;87:3221-3226.
137.
Diez JJ, Iglesias P: Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab 2004;89:4890-4897.
138.
Meyerovitch J, Rotman-Pikielny P, Sherf M, et al: Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 2007;167:1533-1538.
139.
Parle JV, Franklyn JA, Cross KW, et al: Thyroxine prescription in the community: serum thyroid-stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract 1993;43:107-109.
140.
Okosieme OE, Belludi G, Spittle K, et al: Adequacy of thyroid hormone replacement in a general population. QJM 2011;104:395-401.
141.
Flynn RW, Bonellie SR, Jung RT, et al: Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010;95:186-193.
142.
Sawin CT, Geller A, Wolf PA: Low serum thyroid-stimulating hormone concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-1252.
© 2013 European Thyroid Association Published by S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.